Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

Please provide your email address to receive an email when new articles are posted on . Vowst, an oral fecal microbiota product, was approved by the FDA in April. Patients treated with the therapeutic ...

Randomized controlled trials had lower rates of success, but microbiota restoration still out-performed antibiotics. A new meta-analysis of studies examining the use of microbiota restoration to treat ...

Elderly Japanese patients with a high geriatric nutritional risk index (GNRI) were associated with significantly better Clostridioides difficile infection (CDI) relapse-free survival compared with ...

Please provide your email address to receive an email when new articles are posted on . High-dose VE303 prevented more cases of recurrent C. difficile infection compared with a lower dose medication ...

Fecal microbiota transplantation (FMT) was associated with improved mental health outcomes for patients with recurrent Clostridioides difficile infections (CDI), according to a small Dutch ...

Canada: Researchers have found in a new randomized clinical trial that a 4-week vancomycin pulse and taper regimen showed a ...

The addition of bezlotoxumab to fecal microbiota transplantation (FMT) does not provide any clear added benefit in patients with inflammatory bowel disease (IBD) and recurrent Clostridioides difficile ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced ...

Three recent studies tackled strategies aimed at preventing recurrent Clostridium difficile infection (RCDI). Adding a single dose of bezlotoxumab—a monoclonal antibody that neutralized C difficile ...

Medical researchers have found that Fecal Microbiota Transplantation, or FMT, is an optimal cost-effective treatment for first recurrent Clostridioides difficile infection. Research recently published ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...